Cross A J, Crow T J, Perry E K, Perry R H, Blessed G, Tomlinson B E
Br Med J (Clin Res Ed). 1981 Jan 10;282(6258):93-4. doi: 10.1136/bmj.282.6258.93.
The activity of the noradrenergic marker enzyme dopamine-beta-hydroxylase was measured in brains removed postmortem from control patients and patients with Alzheimer's disease. Enzyme activity was decreased in the frontal and temporal cortices and hippocampus in patients with Alzheimer's disease, but was within the normal range in patients with depression, multiinfarct dementia, and terminal coma.The decrease in enzyme activity in Alzheimer's disease may reflect an abnormality of cortical noradrenergic fibres in some patients with the disease.
对对照组患者以及阿尔茨海默病患者死后取出的大脑进行去甲肾上腺素能标记酶多巴胺-β-羟化酶活性的检测。阿尔茨海默病患者额叶、颞叶皮质及海马体中的酶活性降低,但抑郁症患者、多发梗死性痴呆患者及终末期昏迷患者的酶活性处于正常范围内。阿尔茨海默病患者酶活性的降低可能反映了部分该病患者皮质去甲肾上腺素能纤维存在异常。